Physician profile
Ryan Gentzler
NPI 1235390444
$61,784.13
in general payments reported to CMS, 2019-2025
26 companies · $9,946 in 2025
The $9,946 reported for 2025 was more than what 81% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,150 · 2020: $5,681 · 2021: $12K · 2022: $6,735 · 2023: $8,498 · 2024: $9,351 · 2025: $9,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,481 · Travel and Lodging: $1,372 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,838.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,480.86 |
| Travel and Lodging | $1,371.71 |
| Education | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,994.99 | 2019-2025 | Imfinzi, Tagrisso |
| Pfizer INC. | $5,699.56 | 2019 | |
| Daiichi Sankyo INC. | $4,728.75 | 2021-2025 | Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $3,608.00 | 2023 | Exkivity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,552.50 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $2,675.39 | 2023-2024 | Libtayo |
| Gilead Sciences, INC. | $2,570.00 | 2022 | |
| Merck Sharp & Dohme LLC | $2,546.13 | 2023-2025 | |
| Genzyme Corporation | $2,289.00 | 2021 | |
| Blueprint Medicines Corporation | $2,256.25 | 2020 | |
| Amgen INC. | $2,178.54 | 2024 | Imdelltra (Amg 757) |
| Genentech USA, INC. | $1,901.46 | 2024 | Alecensa, Tecentriq |
| Janssen Scientific Affairs, LLC | $1,767.50 | 2022 | |
| Jazz Pharmaceuticals INC. | $1,400.00 | 2021 | |
| Abbvie INC. | $1,087.50 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $292.37 | 2024-2025 | |
| Tempus Ai, INC | $145.74 | 2024 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $48.28 | 2024 | Libtayo |
| Taiho Oncology, INC. | $42.17 | 2025 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gentzler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.